MSB 3.21% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-260

  1. 1,417 Posts.
    lightbulb Created with Sketch. 2124
    That's good biggrin.pngbiggrin.pngbiggrin.png. Or @shakespeare perhaps a soliloquy? Little do they know that when Silviu describes them as "remarkable clinical outcomes", from this guy it doesn't get any more colourfulness and superlativeness - Julie (PR lady) was doing back flips! Me too.

    GLTAH!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.